Abstract

Background: Resistant ovary syndrome (ROS) is a rare endocrine disorder and there have been few reports of live births by affected patients. As gonadotropin resistance leads immature oocytes, some researchers reported few live births with in vitro maturation (IVM) of oocytes, but IVM is not always successful in ROS patients. Here, we report an original case of ROS, associated with Ig-FSHR in the serum, who achieved a live birth following ovarian stimulation combined with dexamethasone treatment.

Case presentation: The 30-year-old woman presented with secondary amenorrhea and infertility. Her serum FSH levels were found to be higher than normal, but in discordance with a normal anti-Müllerian hormone (AMH) level and antral follicle count. Genetic investigation found no mutations potentially affecting FSHR. With reference of previous ROS studies, the patient’s serum was analyzed for antibodies directed against FSHR and dot blot analysis showed strong reactivity with FSHR. Then, dexamethasone was proposed to the patient, and she successfully became pregnant, finally delivering a healthy girl by caesarean section.

Conclusion: To our best knowledge, this is the first report of the successful treatment of ROS using ovarian stimulation combined with dexamethasone. In some cases of ROS, high doses of exogenous gonadotropins in combination with immunosuppressive therapy could be an effective approach.

Keywords: Resistant ovary syndrome, Infertility, Immunosuppressant, Case report, Dexamethasone
in vitro maturation (IVM) [13–15]. However, patients suffering from ROS who fail to produce oocytes following treatment have to be put on a waiting list for oocyte donation [16–22]. Here, we present the case of a patient diagnosed with ROS, who successfully became pregnant and delivered a healthy baby after treatment with high-dose gonadotropin and dexamethasone.

Case presentation

A 30-year-old woman with a body mass index (BMI) of 22.5 was hospitalized due to secondary amenorrhea and infertility. Having been married for 10 years with regular intercourse, she delivered a baby girl in 2009. After that, the patient could not become pregnant again in spite of not using contraception. She experienced amenorrhea for 6 years after giving birth, and had been treated with drugs and contraceptive rings without success. The patient could only adjust her menstrual cycle with medication. The results of basic endocrine examination showed that the serum level of follicle-stimulating hormone (FSH) was high. Examination in April, 2019 (Table 1) indicated that serum FSH was above normal, while the anti-Müllerian hormone (AMH) concentration remained normal. Ultrasound scanning indicated that the uterine volume was relatively small ($4.0 \times 3.9 \times 3.3$ cm), while both ovaries were normal in size and more than 10 antral follicles were observed in both ovaries (Fig. 1). Blood tests and genetic analysis excluded lupus erythematosus, multiglandular insufficiency, diabetes, myasthenia gravis, and chromosomal abnormalities (Fragile X syndrome, Turner syndrome, and Swyer syndrome). The patient had a normal karyotype of 46, XX. Sanger sequencing did not identify associated candidate variants in the FSHR gene. Serological tests, combined with clinical diagnosis and the characteristics of the patient’s infertility suggested ROS.

According to the 5th semen analysis standard of the world health organization, the husband’s sperm concentration and motility were in the normal range, and sperm acrosomal enzyme activity was normal. The study was conducted in accordance with the ethical guidelines of the institution and with the informed consent of the patient.

After admission on March 4th, 2019, the patient underwent two cycles of ovarian hyperstimulation treatment (Table 2, Fig. 2). The first one (May 19, 2019) was initiated with 3.75 mg of GnRH analogue triptorelin acetate injection (Ferring, Switzerland), followed by gonadotropin (300 IU/d, 15d) on cycle day 30. During the ovarian hyperstimulation period, the follicle growth was followed by ultrasound scanning, and the serum hormone levels were determined at the same time. Unfortunately, after 15 days of stimulation, no follicles larger than 14 mm were seen, and this treatment cycle was cancelled.

Due to the failure of the first cycle and a lack of FSHR associated variants in the genetic investigation, we tested the patient’s serum for antibodies directed against FSHR via dot blot analysis, which showed strong reactivity with FSHR (Fig. 3). Consequently, we adjusted the procedure for the second cycle. During the whole period of downregulation and controlled ovarian hyperstimulation, the patient was orally administered dexamethasone at 0.75 mg daily. The second cycle was started on July 6, 2019, at which time the patient was first given a 3.75 mg injection of triptorelin acetate for downregulation on the second day of menstruation. Controlled ovarian hyperstimulation was initiated on day 30 with daily subcutaneous injections of 375 IU of gonadotropin (Gonal F® 225 IU/d plus HMG 150 IU/d)

### Table 1  Laboratory test for hormonal profile

|        | 2019-3-14 | 2019-4-12 | Normal ranges |
|--------|-----------|-----------|---------------|
| FSH    | 42.37     | 40.8      | Early follicular phase (2.5–10.2) IU/L |
| LH     | 15.13     | 11.49     | Early follicular phase (1.9–12.5) IU/L |
| E2     | 15        | 11        | Early follicular phase (11–69) pg/mL |
| AMH    | 6.29      | 6.14      | (2.1–6.5) ng/mL |
| T      | 1.8       | NA        | (0.7–3.1) nmol/L |
| P      | 0.15      | NA        | Early follicular phase (0.38–2.28) ng/mL |
| PRL    | 408.94    | NA        | (72–511) mIU/L |
| FT3    | 4.92      | NA        | (4–10) pmol/L |
| FT4    | 18.39     | NA        | (9–25) pmol/L |
| TSH    | 3.01      | NA        | (0.3–5.0) mIU/L |
| AFC (2–12 mm) | > 20 | 28 | (12–24) |

**Abbreviations:** FSH follicle-stimulating hormone, LH luteinizing hormone, E2 estradiol, AMH anti-Müllerian hormone, T testosterone, P progesterone, PRL prolactin, FT3 free triiodothyronine, FT4 free thyroxine, TSH thyroid stimulating hormone, AFC antral follicle count, NA not applicable
for 3 days, which was then increased to 525 IU (Gonal F® 225 IU/d, HMG 225 IU/d and Luveris 75 IU/d) for 7 days. During the stimulation period, the patient underwent regular ultrasound follicle tracking and hormone measurements (estradiol, luteinizing hormone, follicle-stimulating hormone and progesterone) to monitor follicular maturation. A subcutaneous injection of hCG 10,000 IU (Livzon Pharmaceuticals, China) was administered and oocyte retrieval was scheduled 36 h later, ultrasound guided transvaginal follicular aspiration was performed under negative pressure of 110 mmHg (14.7 kPa) using a single lumen aspiration needle (Cook; William Cook Australia Pty Ltd., Australia). A total of 8 Metaphase II (MII) oocytes were collected. After in vitro fertilization, 3 embryos were vitrified and cryopreserved, and the remaining embryos were discarded.

After 2 months following the second ART cycle, a hormone replacement cycle for endometrial preparation was started on day 3 of menstrual cycle with estradiol valerate tablets (Bayer, Germany, 4 mg for 5 days and then 6 mg for the same period). The addition of oral estradiol (Bayer, Germany) at a dose of 8 mg daily for the next 3 days was successful in achieving an endometrial thickness of 9 mm. The serum E2 on day 16 was 346 pg/ml. Progesterone (0.05 ng/ml) and human chorionic gonadotropin (HCG, 10000 IU) were injected at night. Then, daily progesterone luteal support with

---

**Table 2**  Cycle characteristics and results in patient with resistant ovary syndrome

| Cycle No. | Protocol     | Hormone         | Total gonadotropin (IU) | Days of stimulation | Serum E2 on oocyte retrieval day (pg/mL) | Numbers of follicles (> 14 mm) | MII | D3 embryo | The Result |
|-----------|--------------|-----------------|-------------------------|---------------------|-----------------------------------------|--------------------------------|-----|------------|------------|
| 1         | Long GnRH agonist | Triptorelin Acetate Injection | 3000                    | 15                  | NA                                      | 0                              | NA  | NA         | Cycle the cancel |
| 2         | Long GnRH agonist | Triptorelin Acetate Injection | 4800                    | 11                  | 1973                                    | 8                              | 8   | 3          | Pregnant  |

*Abbreviations: GnRH gonadotropin-releasing hormone, MII metaphase II oocytes, D3 the third day, IU international unit, NA not applicable*
vaginal tablets containing 40 mg of progesterone (Utrogestan, Besins, Paris, France) was started.

One embryo was thawed on day 20 (14 CII, grade II embryo with 14 cells) and transplanted. The serum value of β-hCG was 246.7 mIU/mL on the thirteenth day after the embryo transfer, and vaginal ultrasonography showed clinical pregnancy after 28 days. The pregnancy evolved without complications until the 35th week, at which point the patient exhibited oligohydramnios and gave birth to a baby girl by Caesarean.
found that patients with secondary ROS could achieve pregnancy through periodic estrogen administration [6]. For hormonal therapy of ROS, estradiol, clomiphene, and high-dose hMG are commonly used [18]. However, the response of ROS patients shows significant individual differences. Some cases of ROS could even recover spontaneously [9], while other ROS cases generally presented with amenorrhea, but could become pregnant through hormone therapy more than once [10]. Therefore, the treatment of ROS is also dependent on the severity of the disease.

Some researchers considered that the different basic FSH levels can better reflect the degrees of ovarian follicle resistance to FSH than the follicle numbers [24]. In our opinion, although the grading of ROS according to FSH levels can preliminarily determine the severity of ROS, it is not rigorous, because there were only 6 cases in the report that put this idea forward. Moreover, the case reported by Galvao (14) also proved that a patient with normal FSH levels could show obvious resistance to gonadotropin stimulation. We therefore considered that the FSH level can only reflect the follicular reactivity to ovulation-inducing drugs from one side, which can only be used for reference in the selection of a treatment plan.

The etiology of ROS has not been elucidated, and its pathogenesis may be related to genetic or immunological factors. A number of studies have shown that FSHR mutations are associated with ROS [25–27]. For instance, patients with p.N680S mutation needed a higher dose of FSH stimulation to get the normal serum estrogen level [28–31], suggesting that FSHR (p.N680S) affects the sensitivity of ovaries to FSH, leading to partial “resistance” to FSH. In addition to genetic factors, immunological factors may also contribute to ROS. Studies have shown that there may be auto-antibodies against FSHR, which block the ovaries from responding to gonadotropin stimulation [32–37].

In fact, there was heterogeneity among different ROS patient, and the etiology may involve gene mutations [26, 27] and autoimmune disorders [36, 37]. ROS can only be treated effectively if the causes are clearly identified. Although it was reported that IVM may be a viable treatment option for ROS [15], the etiology of the patients was still unknown. The association between ROS and autoimmune disorders was first proposed in 1982 [36, 37]. The authors found that gonadotropin resistance has the same immune mechanism as myasthenia gravis, and they confirmed that the patient serum contained a substance similar to gamma globulin, which inhibited the specific binding of FSH to the receptor in vitro, possibly explaining the ovary’s non-response to gonadotropin stimulation. In 2004, Chiauzzi et al. found that all the ROS patients had

![Fig. 3](image-url)  
**Fig. 3** Immunoprecipitation followed by western blotting and dot blot analysis of anti-FSHR autoantibodies in the serum of the patient. A polyclonal antibody against FSHR (Abcam, ab113421) in TBST buffer (containing 3% BSA) was used as positive control serum with anti-FSHR autoantibodies, a healthy person’s serum was used as negative control, and sera from the patient before and after the dexamethasone treatment were used to immunoprecipitate recombinant FSH-R protein purified from E. coli (ImmunoClone, IC8974-A). Samples comprising 0.6 μg of FSH-R protein per well were separated on 10% SDS-PAGE gels and then transferred to nitrocellulose membranes. For the dot blot assay, FSH-R protein (100 ng/dot) was applied onto nitrocellulose membranes. The membranes were incubated overnight at 4 °C with serum from the patient and the healthy control, followed by incubation with a horseradish peroxidase (HRP)-conjugated anti-human secondary antibody (Proteintech, SA00001–11) or anti-rabbit secondary antibody (Proteintech, SA00001–2). Stained bands or dots were visualized using Omni-ECL reagent (EpiZyme, SQ201). PC: positive control; BD: before the dexamethasone treatment; AD: after the dexamethasone treatment. NC: negative control; FSH-R: follicle-stimulating hormone receptor.
| Author | Patient No. | Age at intake | Type of infertility | BMI (kg/m2) | Basal AFC | AMH (μg/L) | Ovarian histology | E2 | FSH | Ig-FSHR | Infertility treatments before pregnant | Medication/hormonal pretreatment | Result |
|--------|-------------|---------------|---------------------|-------------|-----------|-------------|-------------------|----|-----|---------|--------------------------------------|---------------------------------|--------|
| Amos, W. L., Jr. (1985) [12] | 1 | 41 | Secondary | NA | NA | NA | NA | NA | 88.4 IU/L | NA | HRT | Estrogens, medroxyprogesterone acetate | Liveborn |
| Jequier, A. M. (1990) [6] | 2 | 28 | Secondary | NA | NA | NA | NA | 31–52 pmol/L | 125 U/L | NA | HRT | 4 cycles (Mestranol + Norethisterone) | Liveborn |
| | 3 | 30 | Secondary | NA | NA | NA | normal ovarian stroma and follicles | 76 pmol/L | range seen in postmenopausal women | NA | HRT | Mestranol + Norethisterone | Normal pregnancy |
| Nawroth, F. and R. Sudik (1999) [8] | 4 | 32 | Secondary | NA | NA | NA | NA | NA | NA | NA | HRT | 2 mg estradiol valerate and 2 mg estradiol valerate/0.15 mg levonorgestrel | Liveborn |
| Mueller, A., et al. (2003) [9] | 5 | 26 | Primary | NA | NA | NA | normal density of follicles | NA | 70 IU/L | NA | HRT | 2 mg estradiol valerate and 0.5 mg norgestrel per day administered sequentially | Liveborn |
| Aslam, M. F., et al. (2004) [10] | 6 | 19 | Secondary | NA | NA | NA | NA | NA | 133.9 IU/L | NA | HRT | 2 mg estradiol valerate and 0.5 mg norgestrel | Twice liveborn |
| | 7 | 24 | Secondary | 27 | NA | NA | NA | NA | Higher than normal | NA | HRT | estradiol valerate and norgestrel (spontaneous recovery of ovarian function after HRT) | Liveborn |
| Zielinska, D. and I. Rzepka-Gorska (2011) [11] | 8 | 31 | Secondary | NA | NA | NA | NA | 18.1 pg/ml | 58.2 IU/mL | NA | HRT | | |
| Ezeh, U. I. O. and A. J. Breeson (1995) [7] | 9 | 32 | 22 | NA | NA | NA | NA | 39 pmol/L | 95–115 IU/L | NA | HRT | Ovarian Hyperstimulation | eight ampoules of menotrophin (Pergonal) daily for 14 days | Liveborn |
| Author                  | Patient No. | Age at intake | Type of infertility | BMI (kg/m2) | Basal AFC | AMH (μg/L) | Ovarian histology | E2 (pg/mL) | FSH (IU/mL) | Ig-FSHR | Infertility treatments before pregnant | Medication/ hormonal pretreatment | Result |
|------------------------|-------------|---------------|---------------------|-------------|-----------|-------------|-------------------|------------|-------------|---------|--------------------------------------|----------------------------------|---------|
| Rogenhofer, N., et al. (2015) [4] | 10          | 26            | Secondary           | 22          | 15        | 2.1         | NA                | 28.7       | 50.8        | NA       | Controlled Ovarian Hyperstimulation and IVM | Narfanelin, recombinant follitropin beta, hMG | Liveborn |
| Grynberg, M., et al. (2013) [13] | 11          | 29            | Primary             | Normal      | 23 and 18 | 4.50 (4.36)  | NA                | <15        | 40.3 (38.4) | NA       | IVM | 17ß-E2, hCG                                      | Liveborn                          |         |
| Li, Y., et al. (2016) [14] | 12          | 33            | Secondary           | NA          | 25        | 12.27       | NA                | 260.57 (141.99) | NA           | NA       | IVM | Estradiol valerate, hCG                      | Liveborn                          |         |
| Galvao, A., et al. (2018) [15] | 13          | 29            | Primary             | 27.7        | 37        | 8.6         | NA                | 27.7 (7.9) | NA          | NA       | IVM | HP-hMG 150IU/day for 5 days, hCG               | Liveborn                          |         |
|                          | 14          | 36            | Primary             | 18.9        | 40        | 2.11        | NA                | 49.1 (7.9) | NA          | NA       | IVM | 17ß-E2, hCG                                      | Liveborn                          |         |
| C. Flageole, et al. (2019) [23] | 15          | 23            | Primary             | 24.8        | 50        | 2.88        | NA                | 43–62 (41.99) | NA          | NA       | IVM | hMG (Menopur®) plus rFSH, (Gonal F®), hCG          | Liveborn                          |         |

Abbreviations: BMI body mass index, AFC antral follicle count, AMH anti-müllerian hormone, HRT hormone replacement therapy, IVM in vitro maturation, ART assisted reproductive technologies, rFSH recombinant follicle stimulating hormone, FSHR follicle-stimulating hormone receptor, GnRH gonadotropin-releasing hormone, hCG human chorionic gonadotropin, hMG human menopausal gonadotropin, HP-hMG highly purified human menopausal gonadotropin, 17ß-E2 estradiol-17ß, NA not applicable

* One live birth after spontaneous birth
circulating immune complexes in the serum, which might block the binding of FSH to its receptor [33].

Although there is evidence that ROS is linked to autoimmune disorders, few cases have been reported in which Ig-FSHR antibodies were detected or corresponding immunotherapy was administered to patients with ROS. In 2015, Rogenhofer described a ROS patient who achieved pregnancy by controlled stimulated ovulation. In their study, resistance to HMG signals was detected in the serum, so they chose recombinant follicle element beta and high purity HMG for ovarian stimulation and obtained a positive response, providing an illustrative case for symptomatic treatment on the basis of a defined cause [4].

In this study, we detected Ig-FSHR antibodies in the patient’s serum [4]. Using a standard long GnRH agonist scheme, with a large dose of gonadotropin combined with immunosuppressive dexamethasone, the patient eventually achieved pregnancy. This result is similar to the treatment method reported by Riestenberg et al. in a primary ovarian insufficiency (POI) patient with polyclandular autoimmune syndrome (PGAS) type 2 [38]. They report a case of successful COH and oocyte cryopreservation with the use of short-term, high-dose prednisone for temporary immune suppression in a patient with presumptive Ig-FSHR associated POI who was initially resistant to stimulation with maximal dosing of gonadotropins, which means the use of corticosteroids for suppression of aberrant autoimmune antibodies may be one of the treatments. Our case report may provide a valuable reference for further ROS treatment.

In general, ROS is closely related to autoimmunity, so we should identify the cause and then carry out targeted treatment, which may greatly increase the success rate of pregnancy in ROS patients. For some patients with abnormal immunity causing ROS, treatment with a large dose of gonadotropin in combination with immunosuppressive agents may be successful.

Abbreviations
ROS: Resistant ovary syndrome; IVF: In vitro fertilization; POF: Premature ovarian failure; FSHR: Follicle-stimulating hormone receptor; FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; AMH: Anti-mullerian hormone; T: Testosterone; P: Progesterone; PRL: Prolactin; FT3: Free triiodothyronine; FT4: Free thyroxine; TSH: Thyroid stimulating hormone; AFC: Antral follicle count; ILU: International unit; GnRH: Gonadotropin-releasing hormone; MI: Metaphase II oocytes; D3: The third day; 14 CII: Grade II embryo with 14 cells; BMI: Body mass index; ART: Assisted reproduction technology; rFSH: Recombinant follicle-stimulating hormone; GnRH: Gonadotropin-releasing hormone receptor; hCG: Human chorionic gonadotropin; hMG: Human menopausal gonadotropin; HP-hMG: Highly purified human menopausal gonadotropin; 170-E2: Estradiol-17β, NA: Not applicable.

Acknowledgements
Authors are grateful Patient Chen for all information presented.

Authors’ contributions
Huiying Li was responsible for drafting the manuscript. Tianli Chang helped to diagnosis, treatment, literature research and manuscript writing. Hongbei Mu helped to write the part of the manuscript and storage of data. Wenpei Xiang contributed to diagnosis, treatment plan and guideline of this study and manuscript revision. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
Full availability of data and material are declared. Extra data is available by emailing Wenpei Xiang.

Declarations
Ethics approval and consent to participate
This survey was approved by the Ethical Committee of Center of Reproductive Medicine Tongji Medical College (2019–04). Informed consents were obtained from participant involved in our study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing of interest.

Author details
1 Institute of Reproductive Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. 2 Center of Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Received: 27 September 2021 Accepted: 30 March 2022
Published online: 07 April 2022

References
1. Evers JL, Rolland R. The gonadotrophin resistant ovary syndrome: a curable disease? Clin Endocrinol. 1981;14(1):99–103.
2. de Moraes-Ruehsen M, Jones GS. Premature ovarian failure. Fertil Steril. 1967;18(4):440–61.
3. Jones GS, De Moraes-Ruehsen M. A new syndrome of amenorrhoea in association with hypergonadotropism and apparently normal ovarian follicular apparatus. Am J Obstet Gynecol. 1969;104(4):597–600.
4. Rogenhofer N, et al. Effective ovarian stimulation in a patient with resistant ovary syndrome and Antigonadotrophin antibodies. Am J Reprod Immunol. 2015;73(2):185–91.
5. Kalilo S, et al. Anti-Mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant oocytes. Hum Reprod. 2012;27(3):654–60.
6. Jequier AA. Conception in the resistant ovary syndrome occurring during hormone replacement therapy: a report of 2 cases. Aust N Z J Obstet Gynaecol. 1990;30(2):176–8.
7. Ezeh UIO, Breeson AJ. Spontaneous pregnancy following pretreatment with gonadotrophins in a patient with resistant ovary syndrome. J Obstetr Gynaecol. 1995;15(6):423–4.
8. Navroth F, Sudik R. Pregnancy and hormone replacement therapy in a patient with resistant ovary syndrome. Zentralbl Gynakol. 1999;121(5):255–7.
9. Mueller A, et al. Spontaneous normalization of ovarian function and pregnancy in a patient with resistant ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2003;111(2):210–3.
10. Aslam MF, Gilmore K, McCune GS. Spontaneous pregnancies in patients with resistant ovary syndrome while on HRT. J Obstetr Gynaecol. 2004;24(3):573–4.
11. Zielińska D, Rzepka-Gorska I. Pregnancy in a patient with resistant ovary syndrome - a case report. Ginekol Pol. 2011;82(10):785–7.
12. Amos WL Jr. Pregnancy in a patient with gonadotropin-resistant ovary syndrome. Am J Obstet Gynecol. 1985;153(2):154–5.
13. Gryenberg M, et al. First birth achieved after in vitro maturation of oocytes from a woman endowed with multiple Antral follicles unresponsive to follicle-stimulating hormone. J Clin Endocrinol Metab. 2013;98(11):4493–8.
14. Li Y, et al. Successful live birth in a woman with resistant ovary syndrome following in vitro maturation of oocytes. J Ovarian Res. 2016;9(1):54.
15. Galvão A, et al. In vitro maturation (IVM) of oocytes in patients with resistant ovary syndrome and in patients with repeated deficient oocyte maturation. J Assist Reprod Genet. 2018;35(12):2161–71.
16. Koninxck PR, Brosens IA. The “gonadotropin-resistant ovary” syndrome as a cause of secondary amenorrhea and infertility. Fertil Steril. 1977;28(9):926–31.
17. Starup J, Pedersen H. Hormonal and ultrastructural observations in a case of resistant ovary syndrome. Acta Endocrinol. 1978;89(4):744–52.
18. Mori H, et al. Sporadic ovulation in a case of resistant ovary syndrome. Asia-Oceania J Obstet Gynaecol. 1985;11(3):357–62.
19. Fraser IS, et al. Resistant ovary syndrome and premature ovarian failure in young women with galactosaemia. Clin Reprod Fertil. 1986;4(2):133–8.
20. Twigg S, Wallman L, McElduff A. The resistant ovary syndrome in a patient with galactosemia: a clue to the natural history of ovarian failure. J Clin Endocrinol Metab. 1996;81(4):1329–31.
21. Sung M, et al. A case of resistant ovary syndrome. Obstetr Gynecol Sci. 2017;52(12):1039–42.
22. Tolino A, Romano L, Montemagno U. Resistant ovary syndrome and fertility. Acta Eur Fertil. 1984;15(3):175–7.
23. Flageole C, et al. Successful in vitro maturation of oocytes in a woman with gonadotropin-resistant ovary syndrome associated with a novel combination of FSH receptor gene variants: a case report. J Assist Reprod Genet. 2019;36(3):425–32.
24. Huang B, et al. Grading and etiology of ovarian resistant syndrome. Chin J Obstet Gynecol. 2017;33(9):963–6.
25. Aittomaki K, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure. Cell. 1995;82(6):959–68.
26. Latronico AC, Arnhold J. Inactivating mutations of LH and FSH receptors--from genotype to phenotype. Pediatr Endocrinol Rev. 2006;4(1):26–31.
27. Li W, et al. Study of two Chinese families affected with resistant ovarian syndrome resulted from novel mutations of FSHR gene. Zhonghua yi xue yi chuan xue za zhi = Journal of medical genetics. 2017;34(2):196–9.
28. Wunsch A, Sonntag B, Simoni M. Polymorphism of the FSH receptor and ovarian response to FSH. Annales D Endocrinologie. 2007;68(2–3):160–6.
29. Grynberg M, et al. First birth achieved after in vitro maturation of oocytes from a woman endowed with multiple Antral follicles unresponsive to follicle-stimulating hormone. J Clin Endocrinol Metab. 2018;35(12):2161–71.
30. Chiauzzi V, et al. Inhibition of follicle-stimulating hormone receptor binding by circulating immunoglobulins. J Clin Endocrinol Metab. 1982;54(6):1221–8.
31. Pabalan N, et al. Evaluating influence of the genotypes in the follicle-stimulating hormone receptor gene (FSHR) Ser680Asn (rs6166) polymorphism on poor and hyper-responders to ovarian stimulation: a meta-analysis. J Ovarian Res. 2014;7:285.
32. Meldrum DR, et al. Ovarian and adrenal steroidogenesis in a virilized patient with gonadotropin-resistant ovaries and hilus cell hyperplasia. Obstet Gynecol. 1980;56(2):216–21.
33. Escobar ME, et al. Development of the gonadotrophic resistant ovary syndrome in myasthenia gravis: suggestion of similar autoimmune mechanisms. Acta Endocrinol. 1982;99(3):431–6.